Enzymatica publ AB (ENZY) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Enzymatica publ AB (ENZY) has a cash flow conversion efficiency ratio of -0.085x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-11.57 Million ≈ $-1.24 Million USD) by net assets (Skr135.68 Million ≈ $14.60 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Enzymatica publ AB - Cash Flow Conversion Efficiency Trend (2009–2024)
This chart illustrates how Enzymatica publ AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Enzymatica publ AB debt and liabilities for a breakdown of total debt and financial obligations.
Enzymatica publ AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Enzymatica publ AB ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sunsuria Bhd
KLSE:3743
|
-0.024x |
|
TROPHY GAMES Development AS
CO:TGAMES
|
0.145x |
|
Territorial Bancorp Inc
NASDAQ:TBNK
|
-0.003x |
|
Teuton Resources Corp.
V:TUO
|
-0.012x |
|
International Development & Investment Corp
VN:IDI
|
-0.101x |
|
Formet Celik Kapi Sanayi ve Ticaret AS
IS:FORMT
|
0.033x |
|
Pancontinental Energy NL
AU:PCL
|
-0.047x |
|
International Media Acquisition Corp
NASDAQ:IMAQ
|
0.023x |
Annual Cash Flow Conversion Efficiency for Enzymatica publ AB (2009–2024)
The table below shows the annual cash flow conversion efficiency of Enzymatica publ AB from 2009 to 2024. For the full company profile with market capitalisation and key ratios, see how much is Enzymatica publ AB worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Skr176.37 Million ≈ $18.98 Million |
Skr-60.51 Million ≈ $-6.51 Million |
-0.343x | +34.76% |
| 2023-12-31 | Skr76.61 Million ≈ $8.24 Million |
Skr-40.29 Million ≈ $-4.34 Million |
-0.526x | -2.86% |
| 2022-12-31 | Skr126.29 Million ≈ $13.59 Million |
Skr-64.57 Million ≈ $-6.95 Million |
-0.511x | -78.12% |
| 2021-12-31 | Skr124.97 Million ≈ $13.45 Million |
Skr-35.87 Million ≈ $-3.86 Million |
-0.287x | -187.36% |
| 2020-12-31 | Skr106.65 Million ≈ $11.48 Million |
Skr-10.65 Million ≈ $-1.15 Million |
-0.100x | +68.32% |
| 2019-12-31 | Skr119.20 Million ≈ $12.83 Million |
Skr-37.58 Million ≈ $-4.04 Million |
-0.315x | -74.80% |
| 2018-12-31 | Skr159.66 Million ≈ $17.18 Million |
Skr-28.79 Million ≈ $-3.10 Million |
-0.180x | +11.46% |
| 2017-12-31 | Skr110.70 Million ≈ $11.91 Million |
Skr-22.55 Million ≈ $-2.43 Million |
-0.204x | +24.73% |
| 2016-12-31 | Skr142.04 Million ≈ $15.29 Million |
Skr-38.43 Million ≈ $-4.14 Million |
-0.271x | +84.20% |
| 2015-12-31 | Skr21.98 Million ≈ $2.37 Million |
Skr-37.65 Million ≈ $-4.05 Million |
-1.712x | -162.87% |
| 2014-12-31 | Skr62.42 Million ≈ $6.72 Million |
Skr-40.67 Million ≈ $-4.38 Million |
-0.651x | +44.40% |
| 2013-12-31 | Skr15.73 Million ≈ $1.69 Million |
Skr-18.43 Million ≈ $-1.98 Million |
-1.172x | -127.13% |
| 2012-12-31 | Skr14.06 Million ≈ $1.51 Million |
Skr-7.25 Million ≈ $-780.54K |
-0.516x | +64.79% |
| 2011-12-31 | Skr3.31 Million ≈ $356.64K |
Skr-4.86 Million ≈ $-522.58K |
-1.465x | -1395.19% |
| 2009-12-31 | Skr-901.48K ≈ $-97.01K |
Skr-101.99K ≈ $-10.98K |
0.113x | -- |
About Enzymatica publ AB
Enzymatica AB (publ), a life science company, develops and sells medical devices for infection-related diseases. The company's product includes ColdZyme, a mouth spray that protects against the upper respiratory viruses that can cause cold and flu symptoms. It also provides enzyme formulations for skin care. The company was incorporated in 2007 and is headquartered in Lund, Sweden.